Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MBC Who Progress on 1L CDK4/6 Inhibitors in Combination With Endocrine Therapy

516 views
November 7, 2024

In this video, Dr. Wassim Mchayleh shares his insights on the unmet needs and challenges faced in HR+, HER2- MBC, including the emergence of resistance mechanisms to ET, either alone or in combination with CDK4/6i.

To access additional videos and download free resources, click here.

VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.

Comments are disabled for this content.